The European Medicines Agency's recent review of finasteride aims to assess the potential connection between the drug and suicidal thoughts, following growing concerns about its psychiatric side effects.
With known risks including depression and suicidal ideation now highlighted in product information, the EMA is evaluating if the current authorizations for finasteride and dutasteride should be maintained or withdrawn.
#medicines-regulation #finasteride #suicidal-ideation #psychiatric-side-effects #european-medicines-agency
Collection
[
|
...
]